Big news for the pursuit of artificial general intelligence — or AI that’s of human-level intelligence across the board. OpenAI, which describes its mission as “ensuring that AGI benefits all of humanity,” finalized its long-in-the-works corporate restructuring plan yesterday. It might entirely change how we approach risks from AI, especially biological ones.

A quick refresher first: OpenAI was originally founded as a nonprofit in 2015, but gained a for-profit arm four years later. The nonprofit will now be named the OpenAI Foundation, and the for-profit subsidiary is now a public benefit corporation, called the OpenAI Group. (PBCs have legal requirements to balance mission and profit, unlike other structures.) The foundation will still control the OpenAI Group and have a 26 percent stake, which was valued at around $130 billion at the closing of recapitalization. (Disclosure: Vox Media is one of several publishers that have signed partnership agreements with OpenAI. Our reporting remains editorially independent.)

“We believe that the world’s most powerful technology must be developed in a way that reflects the world’s collective interests,” OpenAI wrote in a blog post.

One of OpenAI’s first moves — besides the big Microsoft deal — is the foundation putting $25 billion toward accelerating health research and supporting “practical technical solutions for AI resilience, which is about maximizing AI’s benefits and minimizing its risks.”

This story was first featured in the Future Perfect newsletter.

Sign up

© Vox